New oral medicine targeting a pathway to treat idiopathic pulmonary fibrosis
Myocardin-related transcription factor (MRTF) pathway modulators as a novel, disease-modifying oral medicine for idiopathic pulmonary fibrosis (IPF)
This study is looking at a new pill that could help people with idiopathic pulmonary fibrosis (IPF) by targeting a specific pathway in the body, aiming to provide a safer and more effective treatment than what’s currently available.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oncoarendi Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Groton, United States) |
| Project ID | NIH-11078734 on NIH RePORTER |
What this research studies
This research focuses on developing a new oral medication that targets the myocardin-related transcription factor (MRTF) pathway to treat idiopathic pulmonary fibrosis (IPF). The approach aims to create a more effective and safer treatment option compared to existing therapies, which often have limited efficacy and significant side effects. The research involves selecting a promising compound for further studies that could lead to regulatory approval. By addressing the underlying mechanisms of fibrosis, this treatment could potentially modify the disease's progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new, effective treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have performed: Previous research has shown promise in targeting the MRTF pathway for fibrosis treatment, indicating potential for success in this novel approach.
Where this research is happening
Groton, United States
- Oncoarendi Therapeutics, LLC — Groton, United States (Active)
Researchers
- Principal investigator: Golebiowski, Adam — Oncoarendi Therapeutics, LLC
- Study coordinator: Golebiowski, Adam
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.